cat no | io1087, io1088, io1089
A rapidly maturing, consistent and scalable isogenic system to study Parkinson’s disease (PD).
ioGlutamatergic Neurons SNCA A53T/A53T are opti-ox deterministically programmed glutamatergic neurons carrying a genetically engineered homozygous A53T mutation in the SNCA gene encoding the alpha-synuclein protein.
Three clones are available, all genetically matched to the wild type control, ioGlutamatergic Neurons. The disease model cells and the wild type control offer a physiologically relevant model to investigate the impact of the alpha-synuclein mutation on cellular and molecular mechanisms and function.
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
per vial
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
Make True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to directly investigate the effect of the alpha-synuclein mutation on cellular and molecular mechanisms and cell function.
Scalable
With opti-ox technology, we can make billions of consistently programmed cells, surpassing the demands of industrial workflows.
Quick
The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
ioGlutamatergic Neurons SNCA A53T/A53T express neuron-specific markers comparably to the wild type control
ioGlutamatergic Neurons SNCA A53T/A53T form structural neuronal networks by day 11
ioGlutamatergic Neurons SNCA A53T/A53T demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic programming
Disease-related SNCA is expressed in ioGlutamatergic Neurons SNCA A53T/A53T following deterministic programming
bit.bio
V11
bit.bio
2024
Professor Deepak Srivastava
Professor of Molecular Neuroscience and Group Leader, MRC Centre for Developmental Disorders
King’s College London
Emmanouil Metzakopian | Vice President, Research and Development | bit.bio
Javier Conde-Vancells | Director Product Management | bit.bio
Chakraborty et al
Nature Communications
2023
Featuring ioGlutamatergic Neurons
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio
Innovation showcase talk at ISSCR
Marius Wernig MD, PhD | Stanford
Mark Kotter, MD, PhD | bit.bio
Oosterveen, et al
bit.bio & Charles River Laboratories
2023
Qiaojin Lin et al
The EMBO Journal
2023
Featuring opti-ox powered hiPSC-derived glutamatergic neurons with constitutive expression of Cas9
Mark Kotter | CEO and founder | bit.bio
Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology | Stanford University
Madeleine Garrett | Field Application Specialist | bit.bio
Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.
Further your disease research by pairing our wild type cells with isogenic disease models.